1. Introduction {#sec1-marinedrugs-16-00326}
===============

Marine microorganisms have become a promising source of structurally diverse and bioactive compounds \[[@B1-marinedrugs-16-00326],[@B2-marinedrugs-16-00326]\]. Marine *Bacillus* species, which are ubiquitous in the marine ecosystem \[[@B3-marinedrugs-16-00326]\], can produce versatile secondary metabolites that exhibit a wide range of biological activities, such as antimicrobial, anticancer, and antialgal activities \[[@B4-marinedrugs-16-00326],[@B5-marinedrugs-16-00326],[@B6-marinedrugs-16-00326],[@B7-marinedrugs-16-00326]\]. The emergence of microbial resistance to currently available antibiotics makes the treatment of infectious diseases more challenging, and the development of new antimicrobial agents is an urgent need \[[@B8-marinedrugs-16-00326]\].

In a previous study by our group, the ethyl acetate (EtOAc) extract of the culture broth of the strain RJA1515, identified as *Bacillus pumilus*, showed potent antimicrobial activity against Gram-negative bacteria through the inhibition of the enzyme citrate synthase type II \[[@B9-marinedrugs-16-00326]\]. Our ongoing chemical investigation on the same strain led to the isolation of seven long-chain amides including five new compounds, bacillamidins A--E (**1**--**5**), and two previously reported synthetic analogs, bacillamidins F (**6**) and G (**7**) ([Figure 1](#marinedrugs-16-00326-f001){ref-type="fig"}). This paper describes the isolation, the structural elucidation, and the *in vitro* cytotoxicity and antibacterial activity assays of the isolated compounds.

2. Results and Discussion {#sec2-marinedrugs-16-00326}
=========================

The strain *B. pumilus* RJA1515 was cultured in solid agar for 14 days, then the bacterial cultures and the agar were extracted with EtOAc to afford a crude ethyl acetate extract. The extract was fractionated and purified by repeated column chromatography to give bacillamidins A--G (**1**--**7**).

Compound **1** was obtained as a white powder. The molecular formula was determined as C~17~H~31~NO~5~ by high resolution electrospray ionization mass spectrometry (HRESIMS) (*m*/*z* 352.2096 \[M + Na\]^+^, calcd. 352.2100), which indicated three degrees of unsaturation. The ^1^H NMR spectrum ([Table 1](#marinedrugs-16-00326-t001){ref-type="table"}, [Figure S1](#app1-marinedrugs-16-00326){ref-type="app"}) displayed an ABX spin system at *δ*~H~ 4.60 (1H, ddd, *J* = 9.6, 7.6, 6.0 Hz), 2.79 (1H, dd, *J* = 16.4, 9.6 Hz), 2.67 (1H, dd, *J* = 16.4, 6.0 Hz), a proton doublet at *δ*~H~ 8.31 (1H, d, *J* = 7.2 Hz), two methyl doublets at *δ*~H~ 0.84 (6H, d, *J* = 6.4 Hz) and two methoxyl groups at *δ*~H~ 3.61 (3H, s) and 3.60 (3H, s), as well as numerous methylene protons from *δ*~H~ 1.13 to 2.08. The ^13^C NMR and heteronuclear single quantum correlation (HSQC) data of **1** ([Figures S2 and S3](#app1-marinedrugs-16-00326){ref-type="app"}) indicated the presence of two methoxyl carbons (*δ*~C~ 51.6, 52.0), three ester or amide carbonyls (*δ*~C~ 170.4, 171.2, 172.2), two methine sp^3^ (*δ*~C~ 27.3, 48.4), eight methylene sp^3^ (*δ*~C~ 25.1, 26.7, 28.4, 28.7, 29.2, 34.9, 35.6, 38.4) and two methyl (*δ*~C~ 22.5) carbons.

The presence of an alkanone moiety was corroborated by hydrogen-hydrogen correlation spectroscopy (^1^H-^1^H COSY) and heteronuclear multiple bond correlation (HMBC) correlations ([Figure 2](#marinedrugs-16-00326-f002){ref-type="fig"}, [Figures S4 and S5](#app1-marinedrugs-16-00326){ref-type="app"}). The ^1^H-^1^H COSY spectrum showed correlations from the methyl doublet at *δ*~H~ 0.84 (CH~3~-11 and CH~3~-12) to H-10 (*δ*~H~ 1.48), thus, a *gem*-dimethyl terminus was established ([Table 1](#marinedrugs-16-00326-t001){ref-type="table"}). An alkyl chain moiety with eleven carbon atoms was established by HMBC correlations from H-3 (*δ*~H~ 2.08, t, *J* = 7.6 Hz) to C-4 (*δ*~C~ 25.1) and C-5 (*δ*~C~ 28.4) and from the terminal *gem*-dimethyl protons (CH~3~-11 and CH~3~-12) to C-9 (*δ*~C~ 38.4), as well as the presence of a broad singlet, integrated for sixteen methylene protons (H~2~-3 to H~2~-10). The HMBC correlation from H-3 to C-2 (*δ*~C~ 172.2) suggested the connectivity of an alkyl chain to the C-2 amide carbonyl carbon. An amide group was confirmed by the HMBC correlation from the proton doublet of H-1 at *δ*~H~ 8.31 to C-2. The HMBC correlations from H-1 to C-1′ (*δ*~C~ 48.4), from H-1′ (*δ*~H~ 4.60) to C-1″ (*δ*~C~ 170.4) and C-2′ (*δ*~C~ 35.6), and from H-2′a (*δ*~H~ 2.79)/H-2′b (*δ*~H~ 2.67) to C-1′ and C-3′ (*δ*~C~ 171.2) suggested the presence of the aspartic acid moiety \[[@B10-marinedrugs-16-00326]\]. In addition, the HMBC correlations from the two methoxyl groups at *δ*~H~ 3.61 and *δ*~H~ 3.60 to C-1″ and C-3′, respectively, indicated the locations of two methyl ester groups.

The absolute configuration of C-1′ was defined as *R* by comparison of the experimental optical rotation (OR) of **1** (\[α\]${}_{D}^{25}$ −16.6) with the calculated OR of *R*-**1** (\[α\]${}_{D}^{25}$ −15.1), and by comparison of the calculated and the experimental ECD spectra ([Figure 3](#marinedrugs-16-00326-f003){ref-type="fig"}). Thus, the structure of **1** was determined as (1′*R*)-9-methyldecanoyl dimethylaspartate, named bacillamidin A.

Compound **2** was obtained as a white powder. Its molecular formula was established as C~19~H~35~NO~5~ by HRESIMS (*m*/*z* 380.2409 \[M + Na\]^+^, calcd. 380.2413), implying three degrees of unsaturation. The ^1^H and ^13^C NMR spectra of **2** ([Table 1](#marinedrugs-16-00326-t001){ref-type="table"}, [Figures S9 and S10](#app1-marinedrugs-16-00326){ref-type="app"}) resemble those of **1** except for the presence of two additional methylene groups (*δ*~H~ 1.23; *δ*~C~ 29.9, 29.0), one methyl triplet at *δ*~H~ 0.83 (3H, t, *J* = 9.0 Hz), and one methyl doublet *δ*~H~ 0.78 (3H, d, *J* = 9.0 Hz). The ^1^H-^1^H COSY cross-peaks from H-11 (*δ*~H~ 1.23, m) to H-12 (*δ*~H~ 1.10, m) and H-14 (*δ*~H~ 0.78, d, *J* = 9.0 Hz) and from H-12 to H-13 (*δ*~H~ 0.83, t, *J* = 9.0 Hz) and the HMBC correlations ([Figure 2](#marinedrugs-16-00326-f002){ref-type="fig"}, [Figures S12 and S13](#app1-marinedrugs-16-00326){ref-type="app"}) from H-13 to C-12 (*δ*~C~ 29.0) and C-11 (*δ*~C~ 33.7) and from H-14 to C-10 (*δ*~C~ 36.0), C-11, and C-12 indicated that **2** had a terminal *sec*-butyl group in the alkyl chain. All the aforementioned information indicated the presence of a 10-methyldodecanoyl motif in **2**, instead of the 9-methyldecanoyl moiety in **1**. The absolute configuration of C-1′ was established by comparison of the calculated and the experimental ECD spectra ([Figure 4](#marinedrugs-16-00326-f004){ref-type="fig"}). However, the absolute configuration of C-11 was not determined. Thus, the structure of **2** was determined as (1′*R*)-10-methyldodecanoyl dimethylaspartate, named bacillamidin B.

Compound **3** was obtained as a white powder. Its molecular formula was determined as C~17~H~30~N~2~O~3~ by HRESIMS (*m*/*z* 333.2145 \[M + Na\]^+^, calcd. 333.2154), indicating four degrees of unsaturation. The ^1^H NMR spectrum ([Table 2](#marinedrugs-16-00326-t002){ref-type="table"}, [Figure S17](#app1-marinedrugs-16-00326){ref-type="app"}) displayed an ABX spin system at *δ*~H~ 4.35 (1H, ddd, *J* = 9.6, 7.6, 6.0 Hz), 2.84 (1H, dd, *J* = 16.4, 9.6 Hz), 2.53 (1H, dd, *J* = 16.4, 6.0 Hz), a proton doublet at *δ*~H~ 8.42 (1H, d, *J* = 7.6 Hz), one methyl triplet at *δ*~H~ 0.83 (3H, t, *J* = 9.0 Hz), one methyl doublet *δ*~H~ 0.78 (3H, d, *J* = 9.0 Hz), and a singlet of one proton (*δ*~H~ 11.19, s), as well as numerous methylene protons from *δ*~H~ 1.13 to 1.23. The ^13^C NMR and HSQC data of **3** ([Figures S18 and S19](#app1-marinedrugs-16-00326){ref-type="app"}) indicated the presence of three ester or amide carbonyls (*δ*~C~ 172.5, 176.4, 177.7), as well as two methine sp^3^ (*δ*~C~ 33.7, 49.5), ten methylene sp^3^ (*δ*~C~ 25.0, 26.5, 28.5, 28.8, 29.0, 29.0, 29.3, 34.9, 36.0, 36.2), and two methyl carbons (*δ*~C~ 11.2, 19.1). The HMBC correlations from H-1′ (*δ*~H~ 4.35) to C-2′ (*δ*~C~ 177.7), C-4′ (*δ*~C~ 176.4), and C-5′ (*δ*~C~ 36.0) and from H-5′a (*δ*~H~ 2.84)/H-5′b (*δ*~H~ 2.53) to C-4′ and C-2′, in addition to a NH singlet (*δ*~H~ 11.19), suggested the presence of a succimide substructure \[[@B11-marinedrugs-16-00326]\]. The HMBC correlations from NH-1 (*δ*~H~ 8.42, d, 7.6 Hz) to C-1′ (*δ*~C~ 49.5) and C-2′ indicated the linkage between the amide and succimide portion. The ^1^H-^1^H COSY and HMBC spectra ([Figure 5](#marinedrugs-16-00326-f005){ref-type="fig"}, [Figures S20 and S21](#app1-marinedrugs-16-00326){ref-type="app"}) of **3** indicated the same alkyl side chain as a terminal *sec*-butyl group in **2**. The absolute configuration of C-1′ was established by comparison of the calculated and the experimental ECD spectra ([Figure 6](#marinedrugs-16-00326-f006){ref-type="fig"}). The absolute configuration of C-11 was not determined at a current state. Thus, the structure of **3** was determined as (3′*R*)-*N*-(2, 5-dioxopyrrolidin-3-yl)-10-methyldodecamide, named bacillamidin C.

Compound **4** was obtained as a white powder. The molecular formula was determined as C~19~H~34~N~2~O~3~ according to its HRESIMS data (*m*/*z* 361.2461 \[M + Na\]^+^, calcd. 361.2467). The ^1^H and ^13^C NMR, ^1^H-^1^H COSY and HMBC spectra ([Table 2](#marinedrugs-16-00326-t002){ref-type="table"}, [Figures S25, S26, S28 and S29](#app1-marinedrugs-16-00326){ref-type="app"}) showed that the alkyl side chain of **4** possessed a *gem*-dimethyl terminus, similar to that of **1**. The rest ^1^H and ^13^C NMR data of **4** was very similar to those of **3** except for the absence of the NH singlet at *δ*~H~ 11.19 and the presence of a *sec*-butyl moiety (two methyl doublets at *δ*~H~ 0.84, *J* = 6.6 Hz/*δ*~C~ 20.0, a multiplet at *δ*~H~ 1.90, /*δ*~C~ 26.7, and a doublet at *δ*~H~ 3.19, *J* = 7.2 Hz/*δ*~C~ 45.4). Therefore, the structure of **4** was established as shown in [Figure 3](#marinedrugs-16-00326-f003){ref-type="fig"}. The absolute configuration of C-1′ was established by comparison of the calculated and the experimental ECD spectra ([Figure 7](#marinedrugs-16-00326-f007){ref-type="fig"}). Therefore, the structure of **4** was determined as (3′*R*)-*N*-(1-isobutyl-2, 5-dioxopyrrolidin-3-yl)-9-methyldecanamide, named bacillamidin D.

Compound **5** was obtained as a white powder and its molecular formula was established as C~35~H~54~N~2~O~5~ by HRESIMS (*m*/*z* 653.3775 \[M + Na\]^+^, calcd. 653.3778), implying ten degrees of unsaturation. The UV spectrum of **5** showed absorption maxima at 248 and 300 nm which are characteristic of the amicoumacins \[[@B12-marinedrugs-16-00326],[@B13-marinedrugs-16-00326]\]. The ^1^H NMR spectrum ([Table 3](#marinedrugs-16-00326-t003){ref-type="table"}, [Figure S33](#app1-marinedrugs-16-00326){ref-type="app"}) exhibited the signals of the protons of the 1,2,3-trisubstituted benzene ring at *δ*~H~ 7.48 (1H, dd, *J* = 8.4, 7.6 Hz), 6.84 (1H, d, *J* = 8.4 Hz), and 6.82 (1H, d, *J* = 7.6 Hz), three sp^3^ oxymethines at *δ*~H~ 4.69 (1H, ddd, *J* = 10.4, 8.0, 2.8 Hz, H-3′), 4.61 (1H, dd, *J* = 2.4, 2.0 Hz, H-9″), and 4.27 (1H, dd, *J* = 6.0, 2.4 Hz, H-8″), two nitrogen-bearing sp^3^ methines at *δ*~H~ 4.32 (1H, m, H-10″) and 4.19 (1H, dddd, 3.6, 7.6, 10.4, 13.6 Hz, H-5″), a broad peak at *δ*~H~ 1.19 (12H, H-5\~H-10), and three doublets of four methyl groups at *δ*~H~ 0.88 (H-2″), 0.83 (H-15, H-16), and 0.80 (H-1″). The ^13^C NMR spectrum ([Figure S34](#app1-marinedrugs-16-00326){ref-type="app"}) exhibited four ester or amide carbonyls (*δ*~C~ 168.9, 169.8, 171.9, 175.6), three quaternary sp^2^ (*δ*~C~ 108.3, 140.4, 160.8), three methine sp^2^ (*δ*~C~ 115.2, 118.5, 136.2), three oxymethine sp^3^ (*δ*~C~ 71.6, 80.8, 85.7), and two nitrogen-bearing methine sp^3^ (*δ*~C~ 46.1, 48.3) carbons. These NMR data were similar to those of amicoumacin C \[[@B14-marinedrugs-16-00326]\]. The gross structure of **5** was therefore established based on the HSQC and HMBC correlations ([Figure 8](#marinedrugs-16-00326-f008){ref-type="fig"}), indicating that an amicoumacin unit was linked to an alkanone side chain with a *gem*-dimethyl terminus.

The negative sign of the Cotton effect for the n-π\* transition of the carbonyl group at 260 nm in the ECD spectrum ([Figure S42](#app1-marinedrugs-16-00326){ref-type="app"}) was in agreement with the 3′*S* configuration \[[@B13-marinedrugs-16-00326]\]. Moreover, the *J*~H-3′/H-5″~ (10.4 Hz) value was indicative of the trans configuration between H-3′ and H-5″ \[[@B13-marinedrugs-16-00326]\]. In addition, the ECD spectrum of **5** showed a positive Cotton effect at 220 and 242 nm and a negative Cotton effect at 260 and 314 nm, which were in good agreement with those for amicoumacin B and amicoumacin C \[[@B15-marinedrugs-16-00326]\]. Thus, the structure of **5** was determined as (3′*S*,5″*S*,8″*S*,9″*S*,10″*S*)-8′,8″-dihydroxy-9″-oxotetrahydrofuran-10″-yl-13-methyltetradecanamide, named bacillamidin E.

Compounds **6** and **7** were obtained as white powders. Their molecular formulas were determined as C~15~H~31~NO and C~17~H~35~NO according to sodium-adduct ion peaks at *m*/*z* 264.2301 for **6** and 292.2616 for **7**. The structures of **6** and **7** were further established by analyses of their ^1^H, ^13^C, HSQC and HMBC NMR spectral data ([Table S1](#app1-marinedrugs-16-00326){ref-type="app"}, [Figure 9](#marinedrugs-16-00326-f009){ref-type="fig"}, [Figures S43--S46 and S51--S54](#app1-marinedrugs-16-00326){ref-type="app"}) as 13-methyltetradecanamide (bacillamidin F) \[[@B16-marinedrugs-16-00326]\], and 14-methylhexadecanamide (bacillamidin G) \[[@B17-marinedrugs-16-00326]\], respectively. The absolute configuration of C-15 of **7** was not determined at current state. Although **6** and **7** have been already synthesized \[[@B16-marinedrugs-16-00326],[@B17-marinedrugs-16-00326]\], this is the first report of their isolation from a natural source.

The cytotoxic activity against human hepatoma cell line (HepG2), human lung cancer cell line (A549), human breast cancer cell line (MDA-MB-231), and human gastric cancer cell line (SGC7901) and the antibacterial activity against *Pseudomonas aeruginosa* PA-01, *Acinetobacter baumannii* ATCC19606 and *Escherichia coli* BW25113 of **1**--**7** were investigated ([Table 4](#marinedrugs-16-00326-t004){ref-type="table"}). None of the compounds showed significant cytotoxicity in all the cell lines tested. Compounds **1**--**4** showed antibacterial activity against *P. aeruginosa* PA-01 and *A. baumannii* ATCC19606 with minimum inhibitory concentration (MIC) values ranging from 58 to 64 μg/mL.

3. Materials and Methods {#sec3-marinedrugs-16-00326}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00326}
------------------------------------

The melting points were measured on a SGWX-4A microscope (Shanghai Physical-Optics Instruments Co., Shanghai, China). UV spectra were recorded with a Shimadzu UV-260 spectrophotometer (Shimadzu Corp., Kyoto, Japan) in MeOH; *λ*~max~ (log *ε*) in nm. IR spectra were recorded with KBr pellets on an Avatar 360 E.S.P spectrophotometer (Thermo Nicolet Co., Boston, MA, USA). NMR spectra were recorded on a Bruker DRX500 (400 MHz for ^1^H, 100 MHz for ^13^C) spectrometer (Bruker, Bremen, Germany) in DMSO-*d~6~*; *δ* in ppm rel. with Me~4~Si as internal references, and *J* in Hz. HR-ESI-MS was measured with a Xevo G2-S Q-Tof MS (Waters MS Technologies, Manchester, UK) in positive-ion mode; in *m*/*z* (rel. %). ECD measurements were performed using a JASCO J-1500 spectropolarimeter (Jasco Co., Ltd., Tokyo, Japan). Column chromatography (CC) was performed with silica gel (200--300 mesh, Qingdao Marine Chemical Factory, Qingdao, China), Sephadex LH-20 gel (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), and RP silica gel (ODS-A-HG, YMC, Kyoto, Japan). TLC was performed on silica gel plates GF~254~ (Yan-tai Institute of Chemical Technology, Yantai, China). The spots on TLC were visualized by UV light (254 nm) and sprayed with 10% H~2~SO~4~, followed by heating. Semi-preparative high performance liquid chromatography (HPLC) was carried out on a Shimadzu LC-6AD chromatograph (Shimadzu Corp., Kyoto, Japan) with an ODS column (*RP-18*, 250 × 10 mm, YMC, 5 μm) with a flow rate of 2.0 mL/min.

3.2. Strain and Cultivation {#sec3dot2-marinedrugs-16-00326}
---------------------------

*Bacillus pumilus* strain RJA1515 was isolated from marine sediments collected in Bamfield, British Columbia at a depth of 84 m by Raymond J. Andersen's group, in January 2010. The strain was cultured on solid agar at room temperature in 160 pans measuring 50 cm × 30 cm, equivalent to 6.8 L volume of the marine medium 1 (MM1) \[[@B18-marinedrugs-16-00326]\]. After 14 days, the bacterial cultures and the agar were extracted twice with EtOAc (2 × 80 L). Then the extracts were re-dissolved in 2.5 L of EtOAc and back extracted three times with 600 mL of water after being combined and dried in vacuo. The organic fraction was then dried in vacuo to give an extract (32.0 g).

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-16-00326}
-----------------------------

The EtOAc extract (32.0 g) was subjected to an open silica gel column (900.0 g) and eluted with a step gradient of petroleum ether (PE) and EtOAc to yield fourteen fractions (Fr. A--N). The PE/EtOAc (7:3) fraction Fr. H (250.1 mg) was purified on a Sephadex LH-20 column and eluted with CHCl~3~/MeOH (1:3) to give fractions H1 and H2. Fraction H1 (141.3 mg) was fractionated by RP-18 CC (MeOH-H~2~O, from 20:80 to 100:0) to afford fractions H1/1--H1/5. Fraction H1/4 (43.8 mg) was further separated on semi-preparative HPLC with MeOH/H~2~O (0--35 min: 87:13) as eluent to yield **1** (2.2 mg, *t~R~* 15.1 min) and **2** (2.6 mg, *t~R~* 9.0 min). Fraction M (PE-EtOAc, 1:1, 410.8 mg) was chromatographed on RP silica gel CC (25.0 g) with a step gradient of MeOH-H~2~O (20:80--100:0) to obtain fractions M1-5. Fraction M4 was purified by preparative HPLC with MeOH/H~2~O (0--60 min: 78:22) to give **3** (2.1 mg, *t~R~* 42.1 min) and **4** (5.1 mg, *t~R~* 34.9 min). Fraction N (PE-EtOAc, 3:7, 458.9 mg) was chromatographed on RP silica gel CC (25.0 g) with a step gradient of MeOH-H~2~O (20:80--100:0) to give fractions N1-5. Fraction N5 was further purified by semi-preparative HPLC with MeOH/H~2~O (74:26) to obtain **5** (2.8 mg, *t~R~* 25.1 min). Fraction J (PE-EtOAc, 6:4, 699.3 mg) was chromatographed on RP silica gel CC (25.0 g) with a step gradient of MeOH-H~2~O (20:80--100:0) to give five fractions. Fraction J5 (46.4 mg) was further purified by preparative HPLC with MeOH/H~2~O (0--60 min: 87:13) to yield **6** (9.9 mg, *t~R~* 18.3 min) and **7** (3.6 mg, *t~R~* 21.3 min).

Bacillamidin A (**1**): amorphous, white powder; m.p.: 86.8--88.2 °C; \[α\]${}_{D}^{25}$ = −16.6 (*c* 0.20, MeOH); ECD (c = 1.08 mM, MeOH) *λ*~max~ (Δ*ε*): 218 (+4.12); UV (MeOH) *λ*~max~ (log *ε*) 225 (2.85) nm; IR (KBr) *ν*~max~ 3314, 2918, 2851, 1749, 1732, 1649, 1564, 1545, 1435, 1302, 1242, 1163 cm^−1^; ^1^H and ^13^C NMR data, [Table 1](#marinedrugs-16-00326-t001){ref-type="table"}; HRESIMS *m*/*z* 352.2096 \[M + Na\]^+^ (calcd. for C17H31NO5Na, 352.2100).

Bacillamidin B (**2**): amorphous, white powder; m.p.: 85.7--87.1 °C; \[α\]${}_{D}^{25}$ = −16.0 (*c* 0.20, MeOH); ECD (c = 1.02 mM, MeOH) *λ*~max~ (Δ*ε*): 215 (+5.90); UV (MeOH) *λ*~max~ (log *ε*) 225 (2.47) nm; IR (KBr) *ν*~max~ 3314, 2961, 2918, 2851, 1751, 1732, 1647, 1560, 1543, 1435, 1302, 1242, 1211, 1163 cm^−1^; ^1^H and ^13^C NMR data, [Table 1](#marinedrugs-16-00326-t001){ref-type="table"}; HRESIMS *m*/*z* 380.2409 \[M + Na\]^+^ (calcd. for C~19~H~35~NO~5~Na, 380.2313).

Bacillamidin C (**3**): amorphous, white powder; m.p.: 87.8--89.2 °C; \[α\]${}_{D}^{25}$ = −26.1 (*c* 0.20, MeOH); ECD (c = 2.24 mM, MeOH) *λ*~max~ (Δ*ε*): 215 (+10.88), 245 (+7.06); UV (MeOH) *λ*~max~ (log *ε*) 226 (2.62) nm; IR (KBr) *ν*~max~ 3238, 2961, 2922, 2851, 1722, 1703, 1655, 1524, 1416, 1373, 1196, 1171 cm^−1^; ^1^H and ^13^C NMR data, [Table 2](#marinedrugs-16-00326-t002){ref-type="table"}; HRESIMS *m*/*z* 333.2145 \[M + Na\]^+^ (calcd. for C~17~H~30~N~2~O~3~Na, 333.2154).

Bacillamidin D (**4**): amorphous, white powder; m.p.: 91.4--92.6 °C; \[α\]${}_{D}^{25}$ = −24.3 (*c* 0.20, MeOH); ECD (c = 2.00 mM, MeOH) *λ*~max~ (Δ*ε*): 218 (+5.60), +245 (+1.90); UV (MeOH) *λ*~max~ (log *ε*) 226 (2.49) nm; IR (KBr) *ν*~max~ 3238, 2961, 2922, 2851, 1722, 1659, 1520, 1196, 1171 cm^−1^; ^1^H and ^13^C NMR data, [Table 2](#marinedrugs-16-00326-t002){ref-type="table"}; HRESIMS *m*/*z* 361.2461 \[M + Na\]^+^ (calcd. for C~19~H~34~N~2~O~3~Na, 361.2467).

Bacillamidin E (**5**): amorphous, white powder; m.p.: 92.3--93.9 °C; \[α\]${}_{D}^{25}$ = −42.0 (*c* 0.20, MeOH); ECD (c = 0.59 mM, MeOH) *λ*~max~ (Δ*ε*): 220 (+1.49), 226 (−0.47), 242 (+4.48), 260 (−3.92), 314 (−0.74), +341 (0.15); UV (MeOH) *λ*~max~ (log ε) 248 (3.47), 300 (2.95) nm; IR (KBr) *ν*~max~ 3452, 2922, 2853, 1686, 1649, 1566, 1555, 1468, 1412 cm^−1^; ^1^H and ^13^C NMR data, [Table 3](#marinedrugs-16-00326-t003){ref-type="table"}; HRESIMS *m*/*z* 653.3775 \[M + Na\]^+^ (calcd. for C~35~H~54~N~2~O~8~Na, 653.3778).

3.4. ECD Calculation Methods {#sec3dot4-marinedrugs-16-00326}
----------------------------

In general, conformational analyses were carried out via random searching in the Sybyl-X 2.0 using the MMFF94S force field with an energy cutoff of 2.5 kcal/mol. The results showed five lowest energy conformers for **1**--**3**, and six for **4**. Subsequently, the conformers were re-optimized using density functional theory (DFT) at the b3lyp/6-31+g(d) level in gas phase by the GAUSSIAN 09 program. The energies, oscillator strengths, and rotational strengths (velocity) of the first 60 electronic excitations were calculated using the time-dependent DFT methodology at the b3lyp/6-311++g(d,p) level in vacuo. The ECD spectra were simulated by the overlapping Gaussian function (half the bandwidth at 1/e peak height, σ = 0.30 for **1** and **2**, σ = 0.16 for **3**, σ = 0.25 for **4**).

To get the final spectra, the simulated spectra of the conformers were averaged according to the Boltzmann distribution theory and their relative Gibbs free energy (Δ*G*). By comparing the experiment spectrum with the calculated ECD model molecules, the absolute configuration of the only chiral center of all the four compounds was determined to be *R*.

3.5. Bioassay {#sec3dot5-marinedrugs-16-00326}
-------------

Cytotoxicity assays were evaluated on the human tumor cell lines HepG2 (human hepatocellular carcinoma cell line), A549 (human lung carcinoma cell line), MDA231 (human breast carcinoma cells), and SGC7901 (human gastric carcinoma cells) by MTT method according to our previous study \[[@B19-marinedrugs-16-00326]\].

Antimicrobial activity was measured by the liquid broth microdilution method \[[@B20-marinedrugs-16-00326]\] against *Pseudomonas aeruginosa* PA-01, *Acinetobacter baumannii* ATCC19606, and *Escherichia coli* BW25113, with ofloxacin as the positive control.

4. Conclusions {#sec4-marinedrugs-16-00326}
==============

Microorganisms from marine sediments are promising sources of bioactive natural products. Chemical investigation of the marine-derived *Bacillus pumilus* RJA1515 led to the isolation and identification of five new long-chain amides (**1**--**5**) and two previously reported long-chain alkylamides (**6**, **7**). The absolute configuration of **1** was determined by comparison of the calculated and the experimental OR and ECD spectra, while those of **2--5** were determined by comparison of their calculated and the experimental ECD spectra. Compounds **1**--**4** showed antibacterial activity against *P. aeruginosa* PA-01 and *A. baumannii* ATCC19606 with MIC values ranging from 58 to 64 μg/mL.

The following are available online at <http://www.mdpi.com/1660-3397/16/9/326/s1>. This section includes 1D, 2D NMR spectra and other spectroscopic data for compounds **1**--**7**.

###### 

Click here for additional data file.
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###### 

^1^H and ^13^C NMR data (400 and 100 MHz, in DMSO-*d~6~*) of **1** and **2**.

  Position               1                           2                                                  
  ---------------------- --------------------------- ---------------------- --------------------------- --------------
  1-NH                   8.31, d (7.6)                                      8.42, d (7.6)               
  2                                                  172.2, CO                                          172.2, CO
  3                      2.08, t (7.6)               34.9, CH~2~            2.08, t (7.6)               34.9, CH~2~
  4                      1.48, m                     25.1, CH~2~            1.47, m                     25.1, CH~2~
  5                      1.23, m                     28.4, CH~2~            1.23, m                     28.4, CH~2~
  6                      1.23, m                     28.7, CH~2~            1.23, m                     28.7, CH~2~
  7                      1.23, m                     29.2, CH~2~            1.23, m                     28.9, CH~2~
  8                      1.23, m                     26.7, CH~2~            1.23, m                     29.3, CH~2~
  9                      1.13, m                     38.4, CH~2~            1.23, m                     26.4, CH~2~
  10                     1.48, m                     27.4, CH               1.09, m; 1.27, m            36.0, CH~2~
  11                     0.84, d (6.4)               22.5, CH~3~            1.30, m                     33.7, CH
  12                     0.84, d (6.4)               22.5, CH~3~            1.10, m                     29.0, CH~2~
  13                                                                        0.83, t (9.0)               11.2, CH~3~
  14                                                                        0.78, d (9.0)               19.1, CH~3~
  1′                     4.60, ddd (9.6, 7.6, 6.0)   48.4, CH               4.60, ddd (9.6, 7.6, 6.0)   48.4, CH
  2′                     2.79, dd (16.4, 9.6)        35.6, CH~2~            2.79, dd (16.4, 9.6)        35.6, CH~2~
  2.67, dd (16.4, 6.0)                               2.67, dd (16.4, 6.0)                               
  3′                                                 171.2, CO                                          171.3, CO
  3′-OCH~3~              3.61, s                     51.6, OCH~3~           3.61, s                     51.6, OCH~3~
  1″                                                 170.4, CO                                          170.4, CO
  1″-OCH~3~              3.60, s                     52.0, OCH~3~           3.60, s                     52.1, OCH~3~
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###### 

^1^H and ^13^C-NMR data (400 and 100 MHz, in DMSO-*d~6~*) of **3** and **4**.

  Position               3                           4                                                  
  ---------------------- --------------------------- ---------------------- --------------------------- -------------
  1-NH                   8.42, d (7.6)                                      8.51, d (7.6)               
  2                                                  172.5, CO                                          172.6, CO
  3                      2.08, t (7.6)               34.9, CH~2~            2.08, t (7.6)               34.8, CH~2~
  4                      1.23, m                     25.0, CH~2~            1.48, m                     25.0, CH~2~
  5                      1.23, m                     28.5, CH~2~            1.23, m                     28.4, CH~2~
  6                      1.23, m                     28.8, CH~2~            1.23, m                     28.8, CH~2~
  7                      1.23, m                     29.0, CH~2~            1.23, m                     29.2, CH~2~
  8                      1.23, m                     29.3, CH~2~            1.23, m                     26.7, CH~2~
  9                      1.23, m                     26.5, CH~2~            1.13, m                     38.4, CH~2~
  10                     1.09, m; 1.27, m            36.2, CH~2~            1.48, m                     27.4, CH
  11                     1.30, m                     33.7, CH               0.83, d (6.6)               22.5, CH~3~
  12                     1.10, m                     29.0, CH~2~            0.83, d (6.6)               22.5, CH~3~
  13                     0.83, t (9.0)               11.2, CH~3~                                        
  14                     0.78, d (9.0)               19.1, CH~3~                                        
  1′                     4.35, ddd (9.6, 7.6, 6.0)   49.5, CH               4.35, ddd (9.6, 7.6, 6.0)   48.4, CH
  2′                                                 177.7, CO                                          176.5, CO
  3′-NH                  11.19, s                                                                       
  4′                                                 176.4, CO                                          175.2, CO
  5′                     2.84, dd (16.4, 9.6)        36.0, CH~2~            2.91, dd (16.4, 9.6)        34.8, CH~2~
  2.53, dd (16.4, 6.0)                               2.53, dd (16.4, 6.0)                               
  1″                                                                        3.19, d (7.2)               45.4, CH~2~
  2″                                                                        1.90, m                     26.7, CH
  3″                                                                        0.84, d (6.6)               20.0, CH~3~
  4″                                                                        0.84, d (6.6)               20.0, CH~3~
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###### 

^1^H and ^13^C-NMR data (400 and 100 MHz, in DMSO-*d~6~*) of **5**.

  Position   5                                                                                      
  ---------- ---------------------------- ------------- ------- ----------------------------------- -------------
  1-NH       8.34, d (6.8)                              1″      0.80, d (6.4)                       21.3, CH~3~
  2                                       171.9, CO     2″      0.88, d (6.4)                       23.3, CH~3~
  3          1.90, t (7.6)                35.0, CH~2~   3″      1.56, m                             24.0, CH
  4          1.48, m                      24.9, CH~2~   4″      1.32, m                             38.4, CH~2~
  5-10       1.25, m                      28.5--29.2            1.68, m                             
  11         1.25, m                      29.3, CH~2~   5″      4.19, dddd (3.6, 7.6, 10.4, 13.6)   48.3, CH
  12         1.25, m                      26.7, CH~2~   6″-NH   7.94, d (9.6)                       
  13         1.13, m                      38.4, CH~2~   7″                                          169.8, CO
  14         1.49, m                      27.4, CH      8″      4.27, dd (6.0, 2.4)                 71.6, CH
  15         0.83, d, (6.6)               22.5, CH~3~   8″-OH   6.18, d (6.0)                       
  16         0.83, d, (6.6)               22.5, CH~3~   9″      4.61, dd (2.4, 2.0)                 85.7, CH
  1′                                      168.9, CO     10″     4.32, m                             46.1, CH
  3′         4.69, ddd (10.4, 8.0, 2.8)   80.8, CH      11″     2.16, dd (18.0, 2.2)                36.0, CH~2~
  4′         2.87, m                      29.0, CH~2~           2.85, m                             
  5′         6.82, d (7.6)                118.5, CH     12″                                         175.6, CO
  6′         7.48, dd (8.4, 7.6)          136.2, CH                                                 
  7′         6.84, d (8.4)                115.2, CH                                                 
  8′                                      160.8, C                                                  
  8″-OH      10.79, s                                                                               
  9′                                      108.3, C                                                  
  10′                                     140.4, C                                                  
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###### 

Antimicrobial activity of **1**--**7** (MIC, μg/mL).

  Compounds   *P. aeruginosa PA-01*   *A. baumannii* ATCC19606   *E. coli* BW25113
  ----------- ----------------------- -------------------------- -------------------
  **1**       64                      58                         \>128
  **2**       64                      64                         \>128
  **3**       64                      64                         \>128
  **4**       64                      58                         \>128
  **5**       \>128                   \>128                      \>128
  **6**       \>128                   \>128                      \>128
  **7**       \>128                   \>128                      \>128
  ofloxacin   8                       16                         1
